Home LiteratureArticle Details
PMID: 25945010 Published · ppublish English Journal Article

Prognostic value of neutrophil distribution in cholangiocarcinoma.

World journal of gastroenterology ·Vol. 21 ·No. 16 ·2015-04-28 ·Pages 4961-8

Mao ZY, Zhu GQ, Xiong M, Ren L, Bai L

Abstract

To explore the relationship of clinicopathological features and the distribution of neutrophils in the tumor microenvironment with the prognosis of cholangiocarcinoma. Two hundred and fifty-four formalin-fixed and paraffin embedded tissue blocks were analyzed, including tissues from cholangiocarcinoma (n = 254), and tumor adjacent tissues (n = 238). Tissue sections were stained for CD15 using immunohistochemical staining. CD15 expression was detected to identify the distribution of neutrophils in the local tumor microenvironment. The neutrophil density of the tumor tissues and the adjacent tumor tissues was detected to reflect their inflammatory status. Clinical data and follow-up information of cholangiocarcinoma patients who underwent surgery from January 2004 to December 2010 were analyzed retrospectively. The relationship between clinicopathological features and the distribution of neutrophils with prognosis of the patients were analyzed. The positive expression level of CD15 was only significantly related to the TNM stage. CD15 expression was higher in tumor tissues than in adjacent tissues (73.6% vs 54.6%), with significant differences. Patients with high expression of CD15 had significantly shorter overall survival (OS) than those with low expression of CD15 (median overall survival time 39.77 mo vs 16.87 mo, P = 0.008). Patients with high CD15 expression had significantly shorter disease free survival time (DFS) than those with low expression of CD15 (median DFS 38.27 mo vs 16.83 mo, P = 0.029). COX multivariate analysis indicated that high CD15 expression in tumor tissues was an independent risk factor for predicting OS for patients with cholangiocarcinoma [P = 0.012, relative risk (RR) = 1.601], but it was not an independent risk factor for predicting DFS (P = 0.073, RR = 1.462). Patients with high CD15 expression in cancer tissues had shorter DFS and OS. High expression of CD15 is an independent risk factor for OS.

Keywords
CD15 Cholangiocarcinoma Neutrophils Prognosis Surgery Tumor microenvironment
MeSH Terms
Bile Duct Neoplasms/immunology,mortality,pathology,surgery Biomarkers, Tumor/analysis Chi-Square Distribution Cholangiocarcinoma/immunology,mortality,pathology,surgery Disease Progression Disease-Free Survival Female Fucosyltransferases/analysis Humans Immunohistochemistry Kaplan-Meier Estimate Lewis X Antigen/analysis Male Middle Aged Multivariate Analysis Neutrophils/immunology Odds Ratio Predictive Value of Tests Proportional Hazards Models Retrospective Studies Risk Factors Time Factors Treatment Outcome Tumor Microenvironment Up-Regulation
Chemicals
Biomarkers, Tumor Lewis X Antigen FUT4 protein, human Fucosyltransferases
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Mao Zhi-Yuan
Zhi-Yuan Mao, Guang-Qing Zhu, Department of Oncology, Air Force General Hospital of PLA, Beijing 100142, China.
Zhu Guang-Qing
Zhi-Yuan Mao, Guang-Qing Zhu, Department of Oncology, Air Force General Hospital of PLA, Beijing 100142, China.
Xiong Mei
Zhi-Yuan Mao, Guang-Qing Zhu, Department of Oncology, Air Force General Hospital of PLA, Beijing 100142, China.
Ren Li
Zhi-Yuan Mao, Guang-Qing Zhu, Department of Oncology, Air Force General Hospital of PLA, Beijing 100142, China.
Bai Li
Zhi-Yuan Mao, Guang-Qing Zhu, Department of Oncology, Air Force General Hospital of PLA, Beijing 100142, China.
References (50)
50 references, click to expand
  1. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
    Cancer Res. 2005 Oct 1;65(19):8896-904 PMID: 16204061
  2. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21.
    Am J Med Genet. 1992 Apr 15-May 1;43(1-2):428-35 PMID: 1605222
  3. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
    Cancer Res. 2005 Mar 1;65(5):2018-25 PMID: 15753402
  4. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.
    Gastroenterology. 2005 Mar;128(3):620-6 PMID: 15765398
  5. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.
    Cancer. 2005 May 1;103(9):1856-64 PMID: 15779015
  6. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  7. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
    Oncology. 2007;73(3-4):215-20 PMID: 18424885
  8. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.
    Am J Gastroenterol. 2008 Jul;103(7):1716-20 PMID: 18557716
  9. High lifetime risk of cancer in primary sclerosing cholangitis.
    J Hepatol. 2009 Jan;50(1):158-64 PMID: 19012991
  10. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.
    Hepatology. 2009 Jan;49(1):116-23 PMID: 19085911
  11. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
    Br J Cancer. 2009 Apr 21;100(8):1257-66 PMID: 19319137
  12. EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
    J Hepatol. 2009 Aug;51(2):237-67 PMID: 19501929
  13. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
    J Clin Oncol. 2009 Oct 1;27(28):4709-17 PMID: 19720929
  14. Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1.
    Exp Cell Res. 2010 Jan 1;316(1):138-48 PMID: 19747913
  15. Diagnosis and management of primary sclerosing cholangitis.
    Hepatology. 2010 Feb;51(2):660-78 PMID: 20101749
  16. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer.
    Gastric Cancer. 2010 Aug;13(3):170-6 PMID: 20820986
  17. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection.
    J Hepatol. 2011 Mar;54(3):497-505 PMID: 21112656
  18. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  19. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Vasc Interv Radiol. 2011 May;22(5):702-9 PMID: 21514523
  20. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers.
    Transplantation. 2011 Jun 15;91(11):1279-85 PMID: 21617590
  21. Risk factors for cholangiocarcinoma.
    Hepatology. 2011 Jul;54(1):173-84 PMID: 21488076
  22. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer.
    J Surg Oncol. 2011 Oct;104(5):504-10 PMID: 21618251
  23. Cancer surveillance in patients with primary sclerosing cholangitis.
    Hepatology. 2011 Nov;54(5):1842-52 PMID: 21793028
  24. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation.
    J Gastroenterol Hepatol. 2012 Mar;27(3):553-61 PMID: 21913982
  25. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Gastroenterology. 2012 Apr;142(4):1021-1031.e15 PMID: 22178589
  26. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
    Invest New Drugs. 2012 Aug;30(4):1646-51 PMID: 21748296
  27. Targeted therapy for biliary tract cancers.
    J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):326-36 PMID: 22318523
  28. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.
    Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1051-8 PMID: 22653260
  29. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.
    J Clin Invest. 2012 Nov;122(11):3914-8 PMID: 23023701
  30. Immunomonitoring and prognostic relevance of neutrophils in clinical trials.
    Semin Cancer Biol. 2013 Jun;23(3):200-7 PMID: 23403174
  31. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
    Hum Pathol. 2013 Jul;44(7):1216-22 PMID: 23391413
  32. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    Br J Cancer. 2014 Feb 18;110(4):882-7 PMID: 24423918
  33. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
    Jpn J Clin Oncol. 2014 Jun;44(6):570-8 PMID: 24755544
  34. Neutrophils and immunity: challenges and opportunities.
    Nat Rev Immunol. 2006 Mar;6(3):173-82 PMID: 16498448
  35. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 PMID: 16891410
  36. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.
    Int J Cancer. 2007 Feb 1;120(3):638-41 PMID: 17109384
  37. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    J Clin Oncol. 2007 Apr 20;25(12):1562-9 PMID: 17443000
  38. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 PMID: 18077379
  39. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.
    World J Gastroenterol. 2008 Jan 28;14(4):632-5 PMID: 18203300
  40. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.
    Ann Oncol. 2008 Feb;19(2):353-8 PMID: 17962206
  41. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression.
    Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2640-5 PMID: 18268320
  42. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years.
    Cancer. 2000 Aug 1;89(3):523-33 PMID: 10931451
  43. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
    Nat Cell Biol. 2000 Oct;2(10):737-44 PMID: 11025665
  44. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.
    Cancer Causes Control. 2001 Dec;12(10):959-64 PMID: 11808716
  45. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
    J Hepatol. 2002 Mar;36(3):321-7 PMID: 11867174
  46. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.
    Scand J Gastroenterol. 2002 Oct;37(10):1205-11 PMID: 12408527
  47. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  48. Neutrophils and angiogenesis: potential initiators of the angiogenic cascade.
    Chem Immunol Allergy. 2003;83:167-81 PMID: 12947984
  49. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.
    Cancer Sci. 2004 Jul;95(7):592-5 PMID: 15245596
  50. The role of CD15-(Le(X))-related carbohydrates in neutrophil adhesion.
    Histochem J. 1992 Nov;24(11):811-26 PMID: 1362195
Article Info
Journal
World journal of gastroenterology
Abbr.
World J Gastroenterol
ISSN
2219-2840
Published
2015-04-28
Pages
4961-8
Language
English
Region
United States
NLM ID
100883448
PMCID
PMC4408469
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]